<DOC>
	<DOCNO>NCT01300871</DOCNO>
	<brief_summary>This study determine prevalence severity alopecia ( hair loss ) experience postmenopausal breast cancer patient receive endocrine therapy include Tamoxifen , Letrozole ( Femara ) , Exemestane ( Aromasin ) , Anastrozole ( Arimidex ) .</brief_summary>
	<brief_title>Alopecia Secondary Endocrine Therapy Postmenopausal Women With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Alopecia</mesh_term>
	<criteria>Postmenopausal woman Diagnosed hormonereceptor positive breast cancer Commenced adjuvant endocrine therapy â‰¥ 3 month ago , specifically Tamoxifen , Anastrozole , Exemestane , and/or Letrozole Good command English language Under care medical oncologist Princess Margaret Hospital Previously receive chemotherapy Recurrent and/or metastatic disease History endocrine , dermatology , immune system disorder know alter hair growth ( ie . Hypothyroidism iron deficiency )</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>